Nanolive SA announced that Dr. Kimberley Bruce from the University of Colorado Anschutz will explore quantitative label-free readouts for live microglial cells, lipid droplets, and mitochondria in a 35-minute event titled Noninvasive phenotypic screening for Alzheimer's markers in microglia.
Published
Signal category
Research & Knowledge
Quote
“In “Noninvasive phenotypic screening for Alzheimer's markers in microglia”, Dr Kimberley Bruce from the University of Colorado Anschutz will explore quantitative label-free readouts for live microglial cells, lipid droplets, and mitochondria to shed light on the effects of ApoE4, the strongest genetic risk factor for Alzheimer’s disease.”
— Nanolive SA team
Company
Nanolive SA
Capture dynamic, unbiased live cell data to accelerate discovery, development and therapeutics.
- Industry
- Biotechnology Research
- Location
- Tolochenaz, CH
- Company size
- 34 employees
#Nanolive: Capture dynamic, unbiased live cell data to accelerate discovery, development and therapeutics. Nanolive delivers breakthrough 3D imaging solutions that accelerate research in growth industries such as drug discovery and cell therapy. Nanolive’s innovative solutions combine screening, imaging and analysis to radically advance how scientists study living cells and provide novel biological insights such as the mechanisms of cancer and neurodegenerative diseases.
Founded 2013